X BIOSCIENCE PUBLIC COMPANY LIMITEDSET: XBIO🇹🇭 TH
This company's most recent 56-1 One Report was filed as a PDF document (spec v3.0), so SET does not publish its section-by-section detail in a machine-readable form. Some information on this site is therefore incomplete.

News & Press Releases

SET Announcements

20 Nov 2026

Notification convening date of the Public Presentation

Read the full announcement on the SET website ↗
17 Nov 2026

Report on the results of the Exercise of XBIO-W8 (F53-5) (Revised)

Read the full announcement on the SET website ↗
16 Nov 2026

Financial Transaction with Risk to the Financial Position and Operating Performance and Operating Result and Progress Report.

Read the full announcement on the SET website ↗
16 Nov 2026

Financial Performance Quarter 3 (F45) (Reviewed)

Read the full announcement on the SET website ↗
16 Nov 2026

Management Discussion and Analysis Quarter 3 Ending 30 Sep 2026

Read the full announcement on the SET website ↗
16 Nov 2026

Financial Statement Quarter 3/2026 (Reviewed)

Read the full announcement on the SET website ↗
13 Nov 2026

Notification the exercise of XBIO-W8

Read the full announcement on the SET website ↗
13 Nov 2026

Report on the results of the Exercise of XBIO-W8 (F53-5)

Read the full announcement on the SET website ↗
4 Nov 2026

Notification of the Amendment to the 2025 Annual Report ( Form 56-1 One Report )

Read the full announcement on the SET website ↗
30 Oct 2026

The Resignation and Appointment of Directors, Chief Executive Officer and Chief Financial Officer

Read the full announcement on the SET website ↗
15 Oct 2026

Notification the exercise of XBIO-W8

XBIO-W8 warrants can be exercised from 22-Oct-2026 to 29-Oct-2026, with an exercise date of 30-Oct-2026. The exercise price is 0.01567 baht per share, with an exercise ratio of 1 warrant to 2.55221 common shares.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
5 Oct 2026

Notification the final exercise and request for suspension of XBIO-W6

XBIO-W6 warrants have a final exercise date of 04-Jan-2027, with an exercise price of 0.69863 baht per share and an exercise ratio of 1 warrant to 2.14706 common shares. The exercise period is from 20-Dec-2026 to 03-Jan-2027. The stock will trade under a "SP" sign from 09-Dec-2026 to 04-Jan-2027, and the warrants will be delisted on 05-Jan-2027.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
5 Oct 2026

Report on the results of the Exercise of XBIO-W8 (F53-5)

No XBIO-W8 warrants were exercised during the exercise period from 30-Sep-2026 to 30-Sep-2026. The number of unexercised warrants is 222,349,082 units, with 567,481,189 shares remaining reserved.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
29 Sept 2026

Clarification of news or information requested by SET

X Biosciences Public Company Limited clarified to the Stock Exchange of Thailand regarding its financial statements for the second quarter of 2026. The company recognized a cumulative impairment loss of THB 270.63 million on its investment in Fruita Biomed Co., Ltd., due to the counterparty's liquidity constraints and Fruita's operating performance. The Board of Directors approved a revised share sale price of THB 110 per share and an extension of the transaction deadline to June 30, 2027. The company also addressed a THB 88 million short-term loan to a director of a subsidiary, noting corrective actions to ensure regulatory compliance.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
15 Sept 2026

Notification the exercise of XBIO-W8

XBIO-W8 warrants can be exercised from 23-Sep-2026 to 29-Sep-2026, with an exercise date of 30-Sep-2026. The exercise price is 0.01567 baht per share, and the exercise ratio is 1 warrant for 2.55221 common shares.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
15 Sept 2026

Report on the results of the Exercise of XBIO-W8 (F53-5) Revise (Revised)

XBIO-W8 warrants were exercised on 31-Aug-2026, with 10,000,000 units exercised. The exercise resulted in 25,522,100 new common shares at a price of 0.01567 baht per share. Unexercised warrants totaled 222,349,082 units, with 567,481,189 shares remaining reserved.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
14 Sept 2026

Report on the results of the Exercise of XBIO-W8 (F53-5)

XBIO-W8 warrants were exercised on 10,000,000 units from 24-Aug-2026 to 30-Aug-2026 at an exercise price of 0.01567 baht per share. The exercise resulted in 25,522,100 new common shares at a ratio of 1.00 warrant per 2.55221 shares. Unexercised warrants total 222,349,082 units, with 567,481,189 shares remaining reserved.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
7 Sept 2026

Financial Transaction with Risk to the Financial Position and Operating Performance. (Revised)

In Q2 2026, the company reported three financial transactions with risk. Item 1, an impairment of assets held for sale, involved a loss of 123,690.00 thousand baht, with rectification completed. Item 2, doubtful accounts, recorded a loss of 152,539.00 thousand baht and remains under rectification. Item 3, a loss on sale of assets, totaled 28,753.00 thousand baht, with rectification completed.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
31 Aug 2026

Financial Transaction with Risk to the Financial Position and Operating Performance.

The company reported asset impairment, allowance for doubtful accounts, expected credit loss, and write-off of assets totaling 507,554.00 thousand baht in Q2 2026. The loss amount represented 244.10% of operating income of 76,891.00 thousand baht and 643.60% of the net loss of (29,157.00) thousand baht for the quarter. The rectification has been completed.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
31 Aug 2026

Report of the Public Presentation

Read the full announcement on the SET website ↗
24 Aug 2026

Notification convening date of the Public Presentation

The company has scheduled an online public presentation for 28-Aug-2026 at 11:00. The objective is to provide information and a resolving plan for the events where shareholders' equity is < 50% of paid-up capital, and where the company has a loss for 3 consecutive years with shareholders' equity less than 100% of paid-up capital.

Summarised automatically from the announcement filed with SET.

Read the full announcement on the SET website ↗
17 Aug 2026

Notification the exercise of XBIO-W8

Read the full announcement on the SET website ↗
17 Aug 2026

Financial Performance Quarter 2 (F45) (Reviewed) (Revised)

Read the full announcement on the SET website ↗
17 Aug 2026

Management Discussion and Analysis Quarter 2 Ending 30 Jun 2026

Read the full announcement on the SET website ↗
16 Aug 2026

Financial Performance Quarter 2 (F45) (Reviewed)

Read the full announcement on the SET website ↗
16 Aug 2026

Financial Statement Quarter 2/2026 (Reviewed)

Read the full announcement on the SET website ↗
13 Aug 2026

Report on the results of the Exercise of XBIO-W8 (F53-5)

Read the full announcement on the SET website ↗
30 Jul 2026

Report on the use of proceeds from Capital Increase

Read the full announcement on the SET website ↗
22 Jul 2026

Change of company profile

Read the full announcement on the SET website ↗
20 Jul 2026

Clarification of news or information requested by SET

Read the full announcement on the SET website ↗
20 Jul 2026

Notification of the registration of relocation of the Company's head office and the increase of the Company's registered capital to the Department of Business Development, Ministry of Commerce

Read the full announcement on the SET website ↗
20 Jul 2026

Publication of the Minutes of the Extraordinary General Meeting of Shareholders No.2/2026 on the Company's Website

Read the full announcement on the SET website ↗
20 Jul 2026

Notification of the Resolutions of the Company's Board of Directors Meeting No. 10/2026 regarding resignation of Acting CEO, the Appointment of CEO, the Appointment of Company Secretary and the restructuring of the Executive Committee (Revised)

Read the full announcement on the SET website ↗
20 Jul 2026

Notification the exercise of XBIO-W8

Read the full announcement on the SET website ↗
20 Jul 2026

Clarification of news or information requested by SET

Read the full announcement on the SET website ↗
16 Jul 2026

Notification of the Resolutions of the Company's Board of Directors Meeting No. 10/2026 regarding resignation of Acting CEO, the Appointment of CEO, the Appointment of Company Secretary and the restructuring of the Executive Committee

Read the full announcement on the SET website ↗
16 Jul 2026

Notification of the Resolution of the Company's BOD Meeting No. 9/2026 Regarding the Approval of the Disposal of Ordinary Shares in Subsidiary, BAKE and ECT, Constituting a Disposal of Assets Transaction (Revised 2)

Read the full announcement on the SET website ↗
14 Jul 2026

The disposal of the shares in the subsidiary results in the subsidiary ceasing to be a subsidiary of the Company

Read the full announcement on the SET website ↗
10 Jul 2026

The disposal of the shares in the subsidiary results in the subsidiary ceasing to be a subsidiary of the Company

Read the full announcement on the SET website ↗
10 Jul 2026

Notification of the Resolution of the Company's BOD Meeting No. 9/2026 Regarding the Approval of the Disposal of Ordinary Shares in Subsidiary, Bake Cheese Tart (Thailand) Co., Ltd. ("BAKE"), Constituting a Disposal of Assets Transaction (Revised 1)

Read the full announcement on the SET website ↗
7 Jul 2026

Notification of the Resolutions of the Extraordinary General Meeting of Shareholders No. 2/2026

Read the full announcement on the SET website ↗
6 Jul 2026

Report on the results of the Exercise of XBIO-W8 (F53-5)

Read the full announcement on the SET website ↗
2 Jul 2026

Notification of the Resolution of the Company's BOD Meeting No. 9/2026 Regarding the Approval of the Disposal of Ordinary Shares in Subsidiary, Bake Cheese Tart (Thailand) Co., Ltd. ("BAKE"), Constituting a Disposal of Assets Transaction (Revised)

Read the full announcement on the SET website ↗
30 Jun 2026

Clarification of news or information requested by SET

Read the full announcement on the SET website ↗
26 Jun 2026

Disclosure of the Invitation Letter to the Extraordinary General Meeting of Shareholders No. 2/2026 on the Company's Website

Read the full announcement on the SET website ↗
26 Jun 2026

Notification of the Resolution of the Company's BOD Meeting No. 9/2026 Regarding the Approval of the Disposal of Ordinary Shares in Subsidiary, Bake Cheese Tart (Thailand) Co., Ltd. ("BAKE"), Constituting a Disposal of Assets Transaction

Read the full announcement on the SET website ↗
16 Jun 2026

Clarification of news or information requested by SET

Read the full announcement on the SET website ↗
15 Jun 2026

Right Adjustment of XBIO-W6, XBIO-W7, XBIO-W8 (Revised)

Read the full announcement on the SET website ↗
15 Jun 2026

Notification the exercise of XBIO-W8

Read the full announcement on the SET website ↗
15 Jun 2026

Right Adjustment of XBIO-W6, XBIO-W7, XBIO-W8

Read the full announcement on the SET website ↗
8 Jun 2026

Report on the results of the Exercise of XBIO-W8 (F53-5)

Read the full announcement on the SET website ↗
8 Jun 2026

Notification of the BOD Meeting No.8/2026: Resignation & Appointment of Directors, CFO Appointment, Head Office Location, Capital Increase, Issuance of XBIO-W9 to Existing Shareholders, Determination of the Date & Agenda of EGM No. 2/2026 (Revised 2)

Read the full announcement on the SET website ↗
5 Jun 2026

Notification of the BOD Meeting No.8/2026: Resignation & Appointment of Directors, CFO Appointment, Head Office Location, Capital Increase, Issuance of XBIO-W9 to Existing Shareholders, Determination of the Date & Agenda of EGM No. 2/2026 (Revised 2)

Read the full announcement on the SET website ↗
4 Jun 2026

Appointment of a New Director in Replacement of the Resigned Director (Revised)

Read the full announcement on the SET website ↗
4 Jun 2026

Changed information of CFO

Read the full announcement on the SET website ↗
2 Jun 2026

Notification of the BOD Meeting No.8/2026: Resignation & Appointment of Directors, CFO Appointment, Head Office Location, Capital Increase, Issuance of XBIO-W9 to Existing Shareholders, Determination of the Date & Agenda of EGM No. 2/2026 (Revised 1)

Read the full announcement on the SET website ↗
2 Jun 2026

Notification of the BOD Meeting No.8/2026 : Resignation & Appointment of Directors, CFO Appointment, Head Office Location, Capital Increase, Issuance of XBIO-W9 to Existing Shareholders, Determination of the Date & Agenda of EGM No. 2/2026 (Revised)

Read the full announcement on the SET website ↗
2 Jun 2026

Appointment of a New Director in Replacement of the Resigned Director

Read the full announcement on the SET website ↗
2 Jun 2026

Notification of the BOD Meeting No. 8/2026 re: Resignation and Appointment of Directors, CFO Appointment, Headquarter Location, Capital Increase, Issuance of XBIO-W9 to Existing Shareholders, Determination of the Date and Agenda of EGM No. 2/2026

Read the full announcement on the SET website ↗
1 Jun 2026

Report of the Public Presentation

Read the full announcement on the SET website ↗